Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives $20.88 Average Price Target from Analysts

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) have been given a consensus recommendation of “Moderate Buy” by the eight brokerages that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $20.88.

A number of equities analysts have weighed in on TEVA shares. Barclays boosted their price objective on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 18th. StockNews.com lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st.

Insider Activity

In related news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the transaction, the director now owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. This trade represents a 29.15 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.55% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Stifel Financial Corp boosted its holdings in Teva Pharmaceutical Industries by 54.0% during the 3rd quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock valued at $1,196,000 after acquiring an additional 23,283 shares during the period. Thrivent Financial for Lutherans lifted its position in shares of Teva Pharmaceutical Industries by 21.8% during the third quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock worth $4,046,000 after purchasing an additional 40,218 shares in the last quarter. Sio Capital Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the third quarter worth about $24,314,000. CWA Asset Management Group LLC purchased a new position in shares of Teva Pharmaceutical Industries in the fourth quarter valued at approximately $3,340,000. Finally, Two Sigma Advisers LP grew its holdings in shares of Teva Pharmaceutical Industries by 15.3% in the third quarter. Two Sigma Advisers LP now owns 1,034,500 shares of the company’s stock valued at $18,642,000 after purchasing an additional 137,000 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Price Performance

TEVA stock opened at $21.90 on Monday. Teva Pharmaceutical Industries has a 1 year low of $10.83 and a 1 year high of $22.80. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. The firm has a market capitalization of $24.81 billion, a PE ratio of -25.76, a price-to-earnings-growth ratio of 0.99 and a beta of 0.73. The business has a 50 day simple moving average of $19.06 and a 200-day simple moving average of $18.14.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.